Agerea™
(SCRM Bio) — Technical Abstract
A universal excipient platform that prevents stem-cell clumping, enforces tissue-scale dispersion, and improves post-delivery survival
Disclaimer
This material is intended for informational purposes only. It does not constitute an offer to sell or a solicitation of an offer to buy securities. Certain statements contained herein may constitute “forward-looking statements,” subject to risks and uncertainties. All projections and forecasts are based on current knowledge and assumptions and are subject to change without notice.
Note: SCRM Bio, LLC — the subsidiary company that controls exclusive worldwide rights to Agerea™ under license from Texas A&M University — is available for strategic acquisition, or investment partnership.
Scientific Overview
A concise introduction to the scientific foundation and purpose of SCRM Bio.
Mechanism of Action
How SCRM Bio interacts with cells to enhance adhesion, retention, and functional integration.
Structural Validation
Electron microscopy and material analysis confirming the platform’s engineered surface characteristics.
Proof of
Impact
Scientific rationale and emerging evidence supporting improved cell performance and therapeutic potential.
Manufacturing Process
Controlled bioreactor methods used to produce consistent, scalable, and biologically compatible materials.
Comparative Advantage
Key differentiators that position SCRM Bio beyond traditional scaffolds and delivery approaches.
Market Implications
How SCRM Bio may influence treatment accessibility, cost dynamics, and overall cell therapy adoption.
Development Status
Current progress, validation activities, and near-term milestones toward commercialization.
